These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 3325717)

  • 1. Immunotherapeutic effects of local chemotherapy with an active metabolite of cyclophosphamide.
    Scheper RJ; Limpens J; Tan BT; Valster H; Claessen AM; Claessen ME
    Methods Find Exp Clin Pharmacol; 1987 Sep; 9(9):611-5. PubMed ID: 3325717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Local administration of cytostatic drug 4-hydroperoxy-cyclophosphamide (4-HPCY) facilitates cell-mediated immune reactions.
    Boerrigter GH; Scheper RJ
    Clin Exp Immunol; 1984 Oct; 58(1):161-6. PubMed ID: 6478648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor regression and induction of anti-tumor immunity by local chemotherapy of guinea-pigs bearing a line-10 hepatocarcinoma.
    Claessen AM; Valster H; Bril H; Steerenberg PA; Tan BT; Scheper RJ
    Int J Cancer; 1991 Feb; 47(4):626-32. PubMed ID: 1995491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IL-15 mediates anti-tumor effects after cyclophosphamide injection of tumor-bearing mice and enhances adoptive immunotherapy: the potential role of NK cell subpopulations.
    Evans R; Fuller JA; Christianson G; Krupke DM; Troutt AB
    Cell Immunol; 1997 Jul; 179(1):66-73. PubMed ID: 9259773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of cyclophosphamide on immunological control mechanisms.
    Turk JL; Parker D; Cameron AE
    Int J Tissue React; 1984; 6(3):205-11. PubMed ID: 6480267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration.
    Bracci L; Moschella F; Sestili P; La Sorsa V; Valentini M; Canini I; Baccarini S; Maccari S; Ramoni C; Belardelli F; Proietti E
    Clin Cancer Res; 2007 Jan; 13(2 Pt 1):644-53. PubMed ID: 17255288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic vaccination against murine lymphoma by intratumoral injection of naive dendritic cells.
    Song W; Levy R
    Cancer Res; 2005 Jul; 65(13):5958-64. PubMed ID: 15994975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of various cytostatic drugs as local immunotherapeutic agents.
    Scheper RJ; Vos A; de Groot J; Boerrigter GH
    Invest New Drugs; 1984; 2(2):221-5. PubMed ID: 6332093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Enhanced immunogenicity of xenogenized tumor cells in rats pretreated with cyclophosphamide (author's transl)].
    Terashima M
    Hokkaido Igaku Zasshi; 1980 Nov; 55(6):495-9. PubMed ID: 6456215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oxazaphosphorine effects in L 5222 rat leukemia.
    Pohl J; Reissmann T; Voegeli R
    Methods Find Exp Clin Pharmacol; 1987 Sep; 9(9):589-94. PubMed ID: 3437788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined intratumoral injection of bone marrow-derived dendritic cells and systemic chemotherapy to treat pre-existing murine tumors.
    Tong Y; Song W; Crystal RG
    Cancer Res; 2001 Oct; 61(20):7530-5. PubMed ID: 11606390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclophosphamide-induced tumour regression of cyclophosphamide-resistant L5178Y lymphoma through suppressor cells elimination.
    Andrade-Mena CE
    Int J Tissue React; 1994; 16(2):95-103. PubMed ID: 7960506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The serologic response to Meth A sarcoma vaccines after cyclophosphamide treatment is additionally increased by various adjuvants.
    Livingston PO; Jones M; Deleo AB; Oettgen HF; Old LJ
    J Immunol; 1985 Aug; 135(2):1505-9. PubMed ID: 4008930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [New direction in immunochemotherapy of cancer].
    Nitta K
    Gan To Kagaku Ryoho; 1983 Apr; 10(4 Pt 2):1117-28. PubMed ID: 6191674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunostimulatory effects of low-dose cyclophosphamide are controlled by inducible nitric oxide synthase.
    Loeffler M; Krüger JA; Reisfeld RA
    Cancer Res; 2005 Jun; 65(12):5027-30. PubMed ID: 15958544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinct responses of two hepatocellular carcinoma cell lines of a similar origin to immunotherapies targeting regulatory or effector T cells.
    Nagayama Y; Hase W; Motoyoshi Y; Saitoh O; Sogawa R; Nakao K
    Oncol Rep; 2007 May; 17(5):1269-73. PubMed ID: 17390075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells.
    Chapoval AI; Fuller JA; Kremlev SG; Kamdar SJ; Evans R
    J Immunol; 1998 Dec; 161(12):6977-84. PubMed ID: 9862733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complete regression of advanced primary and metastatic mouse melanomas following combination chemoimmunotherapy.
    Kohlmeyer J; Cron M; Landsberg J; Bald T; Renn M; Mikus S; Bondong S; Wikasari D; Gaffal E; Hartmann G; Tüting T
    Cancer Res; 2009 Aug; 69(15):6265-74. PubMed ID: 19622767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative.
    Ghiringhelli F; Larmonier N; Schmitt E; Parcellier A; Cathelin D; Garrido C; Chauffert B; Solary E; Bonnotte B; Martin F
    Eur J Immunol; 2004 Feb; 34(2):336-44. PubMed ID: 14768038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of leukocyte interleukin injection (Multikine) treatment on the peritumoral and intratumoral subpopulation of mononuclear cells and on tumor epithelia: a possible new approach to augmenting sensitivity to radiation therapy and chemotherapy in oral cancer--a multicenter phase I/II clinical Trial.
    Tímár J; Forster-Horváth C; Lukits J; Döme B; Ladányi A; Remenár E; Kásler M; Bencsik M; Répássy G; Szabó G; Velich N; Suba Z; Elõ J; Balatoni Z; Bajtai A; Chretien P; Talor E
    Laryngoscope; 2003 Dec; 113(12):2206-17. PubMed ID: 14660929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.